SAN DIEGO, Jan. 20, 2026 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN) today announced that reimbursement has been granted for its FDA-approved in vitro diagnostic (IVD) TruSight™ Oncology (TSO) Comprehensive test. The reimbursement decision from the Centers for Medicare and Medicaid Services (CMS) will expand access to comprehensive genomic profiling (CGP) and the growing role of personalized genomics in oncology care.

“This decision helps removes barriers that have limited adoption of comprehensive genomic profiling for patients, empowering more healthcare providers to deliver precision oncology insights that will improve outcomes,” said John Fox, MD, senior director, Market Access and Government Affairs at Illumina.